Speaking this week at BIO CEO, the heads of Septerna, Upstream Bio and Actuate Therapeutics shared lessons from going public ...

A STAT examination shows how AI-powered biotechs like Absci and Generate Biomedicines routinely aggrandize their AI ...

Investors know the biotech industry is a waiting game—smaller companies in this space often work to secure the funding to ...

January 2025 kicked off with a wave of impactful biotech deals, setting the stage for an exciting year of innovation.

With a lack of venture capital funding, biotechs are increasingly slashing budget and adapting more virtual principles. Going virtual has been one trend that is gaining popularity in the biotech ...

Backed by Goldman Sachs, Novo Nordisk’s parent company and others, Newleos Therapeutics debuted Thursday with $94 million and ...

Biotech investing can be tricky. Often, the drugs that these fledgling companies produce don’t pan out, and shareholders take ...

Biotech is a high-risk ... What may set this company apart from a host of similar penny stock biotechs, however, is its investigational allogeneic cell therapy being studied in type 1 diabetes.

Locating the company in a biotech incubator helps manage these issues and gives the fledgling business a feeling of independence. Financing spin-out biotechs has been a real challenge over recent ...

Sionna and Odyssey are the fourth and fifth biotech companies to file for IPOs since late December. Over the last three years, however, bursts of IPO activity have typically been followed by longer ...

Merck's (NYSE:MRK) recent acquisition of rights to Chinese biotech LaNova Medicines' cancer ... news for patients and should motivate U.S. biotechs to do the same," they added.